We observed the increasing trend of EDIL3 and decreasing trend of GRP, IL16, PTN, and TAC1 in this training dataset (Figure 3B), and the BC cases were further categorized into “High RS” (with high five-cytokine signature; higher median) or “Low RS” (with low five-cytokine signature; lower median) within the TCGA cohort. This evidence concerns the gene EDIL3 and breast cancer.